 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Effect of Veliparib combined with carboplatin + paclitaxel chemotherapy as the first-line treatment of advanced lung squamous cell carcinoma

J Clin Oncol: Effect of Veliparib combined with carboplatin + paclitaxel chemotherapy as the first-line treatment of advanced lung squamous cell carcinoma

 Last Update: 2021-09-11
 Source: Internet
 Author: User

Tags

cranberry uti treatment

midodrine 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Squamous non-small cell lung cancer (sq NSCLC ) has complex genome features, and there is evidence that some patients with sqNSCLC have DNA damage

NSCLC

Untreated, advanced sqNSCLC patients over 18 years of age were randomly divided into two groups and received carboplatin and paclitaxel combined with Veliparib (120 mg, 2/day) or placebo for up to 6 consecutive courses

OS in smoking patients

In total, a total of 970 patients were randomly assigned to the Veliparib group (n=486; carboplatin+paclitaxel+Veliparib) or placebo group (n=484; carboplatin+paclitaxel+placebo).

Smoking patients did not obtain significant OS benefit from Veliparib treatment (hazard ratio [HR] 0.

OS and PFS in all patients

In the general population, compared with the placebo group, patients in the Veliparib group achieved OS benefits, with a median OS of 12.

In the general population, compared with the placebo group, patients in the Veliparib group received OS benefits, and the median OS was 12.

OS in LP52 positive or negative patients

Among patients with tumor samples available for biomarker evaluation (n=360), LP52-positive patients can obtain significant OS benefit from Veliparib treatment (Veliparib vs placebo median OS: 14.

LP52-positive patients can get significant OS benefits from Veliparib treatment LP52-positive patients can get significant OS benefits from Veliparib treatment, but LP52-negative patients have longer OS in the placebo group than in the Veliparib group, but LP52-negative patients have longer OS in the placebo group Veliparib group

In summary, the total patient population can benefit from OS from this combined study

The total patient population can benefit from OS from this study combination

Original source:

Suresh S.

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.